Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSK2189242A + GSK1024850A
- Development stage
- Discontinued
- Lead developer
- GSK
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
GSK2189242A + GSK1024850A is an experimental combination pneumococcal vaccine developed by GSK Biologicals. It integrates the 10-valent pneumococcal conjugate vaccine (PCV10), marketed as **Synflorix** (GSK1024850A), with a protein-based vaccine component (**GSK2189242A**) containing two conserved pneumococcal proteins: detoxified pneumolysin (dPly) and pneumococcal histidine triad protein D (PhtD). Synflorix provides protection against 10 *Streptococcus pneumoniae* serotypes (1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F) by conjugating their capsular polysaccharides to carrier proteins, including Protein D from non-typeable *Haemophilus influenzae*. The addition of dPly and PhtD was intended to enhance the breadth of protection against non-vaccine serotypes by targeting virulence factors common across most pneumococcal strains. The combination was evaluated in Phase 2 clinical trials for the prevention of invasive pneumococcal disease and otitis media in infants and toddlers, but development was subsequently discontinued.
- Brand names
- Synflorix
- Other names
- dPly-PhtD + PCV1010-valent pneumococcal conjugate vaccine + dPly-PhtDPHiD-CV + dPly-PhtD
02
Targets
CPS (Streptococcus pneumoniae capsular polysaccharide)
Beyond the preview
Go deeper on GSK2189242A + GSK1024850A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSK2189242A + GSK1024850A.